Outcome of Board Meeting

07th November 2026 BSE Limited National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai-400001 Bandra (E), Mumbai-400051 Scrip Code: 533543 Symbol: BROOKS Subject : Outcome of Board Meeting held on Saturday, 07th November 2026. Dear Sir/Madam, Pursuant to provisions of Regulation 30, 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“SEBI Listing Regulations”), we would like to inform you that the Board of Directors of the Company at their Meeting held today i.e. on Saturday, 07th November 2026, which commenced at 2:00 PM and concluded at 4:00 PM have inter alia, considered, approved and taken the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September 2026, along with Limited Review Report issued thereon by the Statutory Auditors of the Company for the quarter and half year ended 30th September 2026. The Financial Results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI Listing Regulations in due course. The above information will also be available on the Company’s website www.brookslabs.net. We request you to kindly take the same on record. Thanking You. Yours faithfully, For BROOKS LABORATORIES LIMITED Bhushan Singh Rana Whole Time Director DIN :10289384 Encl.: As stated Brooks Laboratories Limited Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101 CIN NO: L24232HP2002PLC000267 E-mail : investors@brookslabs.net | Website: www.brookslabs.net Statements of Unaudited Financial Results for the Quarter & Half Year ended 30 September, 2026 (Rs. In Lakhs) Particulars Standalone Consolidated Quarter Ended Half Year Ended Year Ended Quarter Ended Half Year Ended Year Ended 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 Unaudited Unaudited Audited Unaudited Unaudited Audited 1Income Revenue from operations 1,924.79 2 ,296.08 2,345.07 4,220.87 4,896.26 8,573.84 1 ,924.79 2 ,296.08 2 ,345.07 4 ,220.87 4 ,896.26 8 ,573.84 Other Income 9 8 . 4 9 1 7.67 39.02 116.16 60.72 117.05 9 8.49 1 7.67 3 9.02 1 16.16 6 0.72 1 17.05 Total income 2,02 3 . 2 8 2 ,313.75 2 ,384.09 4 ,337.03 4 ,956.98 8 ,690.89 2 ,023.28 2 ,313.75 2 ,384.09 4 ,337.03 4 ,956.98 8 ,690.89 2Expenses (a) Cost of materials consumed 9 10.23 1 ,368.02 1,234.44 2,278.26 2,756.89 4,961.22 9 10.23 1 ,368.02 1 ,234.44 2 ,278.26 2 ,756.89 4 ,961.22 (b) Purchase of Stock in Trade 8 .78 1 4.18 107.70 22.95 187.63 225.07 8 .78 1 4.18 1 07.70 2 2.95 187.63 2 25.07 (c) Change in inventories of finished goods, work-in-progress and stock-in-trade 2 01.57 ( 114.01) 2 9.01 87.56 1 5.88 ( 84.10) 2 01.57 ( 114.01) 2 9.01 8 7.56 1 5.88 ( 84.10) (d) Employees benefits expenses 4 16.42 4 21.28 392.82 837.70 759.68 1,516.21 4 16.42 4 21.28 3 92.82 8 37.70 7 59.68 1 ,516.21 (e) Finance Costs 2 5.19 2 0.55 28.34 45.74 58.48 83.53 2 5.19 2 0.55 2 8.34 4 5.74 5 8.48 8 3.53 (f) Depreciation and amortization expenses 44.76 4 1.53 39.24 86.29 78.43 158.99 4 4.76 4 1.53 3 9.24 8 6.29 7 8.43 1 58.99 (g) Other expenses 3 55.83 4 20.34 328.81 776.17 611.20 1,249.47 3 55.83 4 20.34 3 28.81 7 76.17 6 11.20 1 ,249.47 Total Expenses 1 ,962.78 2 ,171.89 2 ,160.36 4 ,134.67 4 ,468.19 8 ,110.39 1 ,962.78 2 ,171.89 2 ,160.36 4 ,134.67 4 ,468.19 8 ,110.39 3 Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax 60.50 1 41.86 2 23.73 2 02.36 4 88.79 5 80.50 6 0.50 1 41.86 2 23.73 2 02.36 4 88.79 5 80.50 4Share of Profit / (Loss) from Jointly controlled entities and associates (Refer note 3) - - - - - ( 237.82) ( 320.55) 5 73.96 ( 558.37) 1 ,267.38 1 ,877.85 Profit/(Loss) before Exceptional item and tax 6 0.50 1 41.86 2 23.73 2 02.36 4 88.79 5 80.50 ( 177.32) ( 178.69) 7 97.69 ( 356.01) 1 ,756.17 2 ,458.35 5Exceptional items income / (expense) (Refer note 5) 7 ,470.00 - - 7 ,470.00 - - 7 ,470.00 - - 7 ,470.00 - - 6 Profit/(Loss) from ordinary activities before tax 7 ,530.50 1 41.86 2 23.73 7 ,672.36 4 88.79 5 80.50 7 ,292.68 ( 178.69) 7 97.69 7 ,113.99 1 ,756.17 2 ,458.35 7Tax Expense: Current tax 5 3 1 . 6 8 - - 5 31.68 - - 5 31.68 5 31.68 Deferred Tax Liability / (Assets) (Refer note 6) - - - - - - - - - - - - MAT credit reversal - - - - - - - - - - - - Tax of earlier years - - - - - - - - - - - - 8Net Profit/(loss) after tax 6,998.82 1 41.86 2 23.73 7 ,140.68 4 88.79 5 80.50 6 ,761.00 ( 178.69) 7 97.69 6 ,582.31 1 ,756.17 2 ,458.35 9Other Comprehensive Income Items That will not be reclassified into Profit or loss Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax) - - - - - ( 3.07) - - - - - ( 3.07) 10Total Comprehensive income for the period 6,998.82 1 41.86 2 23.73 7 ,140.68 4 88.79 5 77.43 6 ,761.00 ( 178.69) 7 97.69 6 ,582.31 1 ,756.17 2 ,455.28 Net Profit attributable to Owners of equity - - - - 6 ,761.00 ( 178.69) 7 97.69 6 ,582.31 1 ,756.17 2 ,458.35 Non Controlling Interest - - - - - - - - - - Other Comprehensive Income attributable to : Owners of equity - - - - - - - - - ( 3.07) Non Controlling Interest - - - - - - - - - - Total Comprehensive Income attributable to Owners of Equity - - - - 6 ,761.00 ( 178.69) 7 97.69 6 ,582.31 1 ,756.17 2 ,455.28 Non Controlling Interest - - - - - - - - - 11Paid-up equity share capital (Face Value of Rs. 10 each) 2 ,945.72 2 ,945.72 2 ,945.72 2 ,945.72 2 ,945.72 2,945.72 2 ,945.72 2 ,945.72 2 ,945.72 2 ,945.72 2 ,945.72 2 ,945.72 12Reserves excluding Revaluation Reserves 9,138.68 9,319.99 13Earnings per share (of Rs. 10/- each) (not annualized) (a) Basic 2 3.76 0 .48 0 .76 2 4.24 1 .66 1 .97 2 2.95 ( 0.61) 2 .71 2 2.35 5 .96 8 .35 (b) Diluted 2 3.76 0 .48 0 .76 2 4.24 1 .66 1 .97 2 2.95 ( 0.61) 2 .71 2 2.35 5 .96 8 .35 Notes: 1 The above Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on November 07, 2026 2 The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevent rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July, 2016 3 Brooks Steriscience Limited (BSL), a jointly controlled entity, recorded revenue from operations of Rs. 4,240.43 lakhs for the half year ended September 30, 2026, and incurred a loss after tax of Rs. 1,166.04 lakhs. Accordingly, the Company's share of loss after tax amounting to Rs. 558.37 lakhs has been recognised in the consolidated financial results for the half year ended September 30, 2026. Consequent to the reduction in the Company's shareholding in BSL from 49.00% to 37.52% during the quarter ended September 30, 2026, the Company's share of loss has been determined on a time-weighted basis. 4 The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures". 5 DuringthequarterandhalfyearendedSeptember30,2026theCompanyhaspartiallydivesteditsequitystakeinBrooksSteriscienceLimitedbyselling36,000equityshares,representing11.48%oftheequitysharecapitaloftheinvesteecompany,foranaggregateconsiderationofRs.7,473.60Lakhs.Pursuanttothe aforesaid transaction, the Company has recognised a gain of Rs.7,470.00 Lakhs (net of the proportionate carrying value of the investment), which has been separately disclosed as an exceptional item in the Statement of Profit and Loss. Followingtheaforesaiddivestment,theCompanycontinuestohold37.52%equitystakeintheinvesteecompanyandretainssignificantinfluenceoveritsrelevantactivities.Accordingly,theretainedinvestmentcontinuestobeaccountedforusingtheequitymethodinaccordancewithIndAS28–Investmentsin A [Showing first 8,000 characters — download PDF for full document]